Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.15
-0.11 (-0.77%)
Aug 14, 2025, 2:16 PM - Market open
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 85.45B INR in the quarter ending June 30, 2025, with 11.37% growth. This brings the company's revenue in the last twelve months to 334.26B, up 15.86% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
334.26B INR
Revenue Growth
+15.86%
P/S Ratio
3.08
Revenue / Employee
12,018,985 INR
Employees
27,811
Market Cap
11.99B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RDY News
- 21 days ago - Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Dr. Reddy's Q1FY26 Financial Results - Business Wire
- 22 days ago - India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says - Reuters
- 2 months ago - Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
- 2 months ago - Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) - Business Wire
- 3 months ago - Dr. Reddy's Continues To Be A Good Buy At Current Valuation - Seeking Alpha
- 3 months ago - Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Dr. Reddy's Q4 & Full Year FY25 Financial Results - Business Wire